COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Canadian Aesthetic Experience With Sculptra Therapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00447551
Recruitment Status : Completed
First Posted : March 14, 2007
Last Update Posted : November 19, 2019
Information provided by (Responsible Party):
Bausch Health Americas, Inc.

Brief Summary:

Primary objective To evaluate the degree of correction achievable with Sculptra for nasolabial folds, mid- and lower facial volume loss, jawline laxity and other signs of facial ageing.

To document the types and incidence of device-related adverse events with Sculptra.

Condition or disease Intervention/treatment Phase
Skin Aging Drug: Poly-L-Lactic Acid Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 76 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Canadian Study of the Use of Injectable POLY-L-LACTIC Acid (Sculptra Therapy) in Aesthetic Medicine
Study Start Date : January 2007
Actual Primary Completion Date : April 2008
Actual Study Completion Date : April 2008

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: single group Drug: Poly-L-Lactic Acid
Deep dermal injection
Other Name: Sculptra

Primary Outcome Measures :
  1. Evaluate the degree of correction attainable with Sculptra (injectable PLLA) for the correction of nasolabial folds, mid-and lower facial volume loss, jawline laxicity, and other signs of facial aging. [ Time Frame: From baseline to 6-months post-Sculptra therapy ]

Secondary Outcome Measures :
  1. Document the types and incidence of device adverse events with Sculptra Therapy (Injectable PLLA) [ Time Frame: From baseline to 6-months post-Sculptra therapy ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Present with nasolabial folds, mid- and lower facial volume loss, jawline laxity or other signs of facial ageing to be treated with Sculptra
  • The subject must be willing and able to provide written informed consent that includes a release for use of their photographs in publications. Subjects who refuse the photo release will not be eligible to participate in the study.
  • Female subjects must be post-menopausal for at least one year or have had a hysterectomy or tubal ligation; if of child-bearing potential, must agree to use an approved method of birth control throughout the study (i.e., oral/systemic contraceptives, intrauterine device (IUD), or spermicide in combination with a barrier method of contraception);

Exclusion Criteria:

  • Personal history of allergic/anaphylactic reactions, including hypersensitivity to local anaesthetics (lidocaine);
  • Known history of bleeding disorders;
  • Active inflammatory process in the area to be treated (skin eruptions such as cysts, pimples, rashes, cancerous/pre-cancerous lesions, or any other active skin disease);
  • Active hepatitis within the past year;
  • Subjects who are pregnant or who plan to become pregnant within the study timeframe, or who are breastfeeding;
  • HIV positive patients;
  • Recent history of trauma in the face (< 1 year);
  • Previous use of Dermalive or Dermadeep;
  • Previous facial surgery within the last six months;
  • Recent facial filler within the last six months;
  • Planned surgical interventions (such as rhinoplasty, facelift, congenital defect repair) or use of other fillers or lasers for the initial six months post-Sculptra therapy;
  • Subjects with clinically important disease as judged by the investigator within 3 months of the start of the study (e.g., history of significant lab abnormalities, myocardial infarct, stroke, cancer, connective tissue disease, etc.), including subjects with medical conditions that might require the use of immunosuppressive medications during the trial (severe asthma, rheumatoid arthritis, organ transplant, etc.);
  • Subjects who have used superficial dermal resurfacing procedures in the facial area, including chemical peel, dermabrasion, or microderm treatments within six weeks of visit 1 and for the duration of the main study.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00447551

Layout table for location information
Sanofi-Aventis Administrative Office
Québec, Canada
Sponsors and Collaborators
Bausch Health Americas, Inc.
Layout table for investigator information
Study Director: Mary Tzortzis Sanofi
Layout table for additonal information
Responsible Party: Bausch Health Americas, Inc. Identifier: NCT00447551    
Other Study ID Numbers: POLYL_L_01777
First Posted: March 14, 2007    Key Record Dates
Last Update Posted: November 19, 2019
Last Verified: November 2019
Keywords provided by Bausch Health Americas, Inc.:
Aesthetic facial volume enhancement